Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

جینکو بیلوبا برای درمان لنگش متناوب

Información

DOI:
https://doi.org/10.1002/14651858.CD006888.pub3Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 07 junio 2013see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:
  1. Grupo Cochrane de Vascular

Copyright:
  1. Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Saskia PA Nicolaï

    Department of General Practice, Maastricht University, Maastricht, Netherlands

  • Lotte M Kruidenier

    Department of Vascular Surgery, Catharina Hospital, Eindhoven, Netherlands

  • Bianca LW Bendermacher

    Department of Vascular Surgery, Catharina Hospital, Eindhoven, Netherlands

  • Martin H Prins

    Department of Epidemiology, CAPHRI Research School, Maastricht University, Maastricht, Netherlands

  • Rutger A Stokmans

    Department of Vascular Surgery, Catharina Hospital, Eindhoven, Netherlands

    Department of Epidemiology, CAPHRI Research School, Maastricht University, Maastricht, Netherlands

  • Pieter PHL Broos

    Department of Vascular Surgery, Catharina Hospital, Eindhoven, Netherlands

  • Joep AW Teijink

    Correspondencia a: Department of Vascular Surgery, Catharina Hospital, Eindhoven, Netherlands

    [email protected]

    Department of Epidemiology, CAPHRI School for Public Health and Primary Care, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands

Contributions of authors

Saskia Nicolaï and Lotte Kruidenier independently selected trials for inclusion, assessed study quality and extracted data. Bianca Bendermacher checked all results for accuracy. Martin Prins and Joep Teijink resolved disagreements. For the 2013 update, Rutger Stokmans and Pieter Broos independently selected trials for inclusion.

Sources of support

Internal sources

  • No sources of support supplied

External sources

  • Chief Scientist Office, Scottish Government Health Directorates, Scottish Government, UK.

    The PVD Group editorial base is supported by the Chief Scientist Office.

Declarations of interest

MP reports his institution has received funds for his Board membership of clinical studies and invited speaker activities from Bayer, Pfizer, Leo, Daichi Sankyo and Sanofi‐Aventis. These were not related to this review.

Acknowledgements

None

Version history

Published

Title

Stage

Authors

Version

2013 Jun 07

Ginkgo biloba for intermittent claudication

Review

Saskia PA Nicolaï, Lotte M Kruidenier, Bianca LW Bendermacher, Martin H Prins, Rutger A Stokmans, Pieter PHL Broos, Joep AW Teijink

https://doi.org/10.1002/14651858.CD006888.pub3

2009 Apr 15

Ginkgo biloba for intermittent claudication

Review

Saskia PA Nicolaï, Lotte M Kruidenier, Bianca LW Bendermacher, Martin H Prins, Joep AW Teijink

https://doi.org/10.1002/14651858.CD006888.pub2

2008 Jan 23

Ginkgo biloba for intermittent claudication

Protocol

Saskia PA Nicolaï, Lotte M Kruidenier, Bianca LW Bendermacher, Martin H Prins, Joep AW Teijink

https://doi.org/10.1002/14651858.CD006888

Notes

This review has been marked stable and will only be updated if new studies are identified.

Keywords

MeSH

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Methodological quality summary: review authors' judgments about each methodological quality item for each included study.
Figuras y tablas -
Figure 1

Methodological quality summary: review authors' judgments about each methodological quality item for each included study.

Methodological quality graph: review authors' judgments about each methodological quality item presented as percentages across all included studies.
Figuras y tablas -
Figure 2

Methodological quality graph: review authors' judgments about each methodological quality item presented as percentages across all included studies.

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.1 Absolute claudication distance (expressed as kilocalories) at the end of the study.
Figuras y tablas -
Figure 3

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.1 Absolute claudication distance (expressed as kilocalories) at the end of the study.

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.2 Absolute claudication distance (expressed as kilocalories) after 24 weeks.
Figuras y tablas -
Figure 4

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.2 Absolute claudication distance (expressed as kilocalories) after 24 weeks.

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.3 Absolute claudication distance (expressed as kilocalories) after 12 to 16 weeks.
Figuras y tablas -
Figure 5

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.3 Absolute claudication distance (expressed as kilocalories) after 12 to 16 weeks.

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.4 Absolute claudication distance (expressed as kilocalories) after 6 to 8 weeks.
Figuras y tablas -
Figure 6

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.4 Absolute claudication distance (expressed as kilocalories) after 6 to 8 weeks.

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.5 Initial claudication distance (expressed as kilocalories) at the end of the study.
Figuras y tablas -
Figure 7

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.5 Initial claudication distance (expressed as kilocalories) at the end of the study.

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.6 Initial claudication distance (expressed as kilocalories) after 24 weeks.
Figuras y tablas -
Figure 8

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.6 Initial claudication distance (expressed as kilocalories) after 24 weeks.

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.7 Initial claudication distance (expressed as kilocalories) after 12 to 16 weeks.
Figuras y tablas -
Figure 9

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.7 Initial claudication distance (expressed as kilocalories) after 12 to 16 weeks.

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.8 Initial claudication distance (expresses as kilocalories) after 6 to 8 weeks.
Figuras y tablas -
Figure 10

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.8 Initial claudication distance (expresses as kilocalories) after 6 to 8 weeks.

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.9 Ankle brachial index and ankle pressure at the end of study.
Figuras y tablas -
Figure 11

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.9 Ankle brachial index and ankle pressure at the end of study.

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.10 Quality of life (expressed as a Visual Analogue Scale for complaints).
Figuras y tablas -
Figure 12

Forest plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.10 Quality of life (expressed as a Visual Analogue Scale for complaints).

Funnel plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.1 Absolute claudication distance (expressed as kilocalories) at the end of the study. On the horizontal axis the effect estimate of Ginkgo biloba versus placebo on the absolute claudication distance at the end of the study is presented as the mean difference. The vertical axis presents the standard error of the intervention effect on a reversed scale.
Figuras y tablas -
Figure 13

Funnel plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.1 Absolute claudication distance (expressed as kilocalories) at the end of the study. On the horizontal axis the effect estimate of Ginkgo biloba versus placebo on the absolute claudication distance at the end of the study is presented as the mean difference. The vertical axis presents the standard error of the intervention effect on a reversed scale.

Funnel plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.2 Absolute claudication distance (expressed as kilocalories) after 24 weeks. On the horizontal axis the effect estimate of Ginkgo biloba versus placebo on the absolute claudication distance after 24 weeks is presented as the mean difference. The vertical axis presents the standard error of the intervention effect on a reversed scale.
Figuras y tablas -
Figure 14

Funnel plot of comparison: 1 Ginkgo biloba versus placebo, outcome: 1.2 Absolute claudication distance (expressed as kilocalories) after 24 weeks. On the horizontal axis the effect estimate of Ginkgo biloba versus placebo on the absolute claudication distance after 24 weeks is presented as the mean difference. The vertical axis presents the standard error of the intervention effect on a reversed scale.

Comparison 1 Ginkgo biloba versus placebo, Outcome 1 Absolute claudication distance (expressed as kilocalories) at the end of the study.
Figuras y tablas -
Analysis 1.1

Comparison 1 Ginkgo biloba versus placebo, Outcome 1 Absolute claudication distance (expressed as kilocalories) at the end of the study.

Comparison 1 Ginkgo biloba versus placebo, Outcome 2 Absolute claudication distance (expressed as kilocalories) after 24 weeks.
Figuras y tablas -
Analysis 1.2

Comparison 1 Ginkgo biloba versus placebo, Outcome 2 Absolute claudication distance (expressed as kilocalories) after 24 weeks.

Comparison 1 Ginkgo biloba versus placebo, Outcome 3 Absolute claudication distance (expressed as kilocalories) after 12 to 16 weeks.
Figuras y tablas -
Analysis 1.3

Comparison 1 Ginkgo biloba versus placebo, Outcome 3 Absolute claudication distance (expressed as kilocalories) after 12 to 16 weeks.

Comparison 1 Ginkgo biloba versus placebo, Outcome 4 Absolute claudication distance (expressed as kilocalories) after 6 to 8 weeks.
Figuras y tablas -
Analysis 1.4

Comparison 1 Ginkgo biloba versus placebo, Outcome 4 Absolute claudication distance (expressed as kilocalories) after 6 to 8 weeks.

Comparison 1 Ginkgo biloba versus placebo, Outcome 5 Initial claudication distance (expressed as kilocalories) at the end of the study.
Figuras y tablas -
Analysis 1.5

Comparison 1 Ginkgo biloba versus placebo, Outcome 5 Initial claudication distance (expressed as kilocalories) at the end of the study.

Comparison 1 Ginkgo biloba versus placebo, Outcome 6 Initial claudication distance (expressed as kilocalories) after 24 weeks.
Figuras y tablas -
Analysis 1.6

Comparison 1 Ginkgo biloba versus placebo, Outcome 6 Initial claudication distance (expressed as kilocalories) after 24 weeks.

Comparison 1 Ginkgo biloba versus placebo, Outcome 7 Initial claudication distance (expressed as kilocalories) after 12 to 16 weeks.
Figuras y tablas -
Analysis 1.7

Comparison 1 Ginkgo biloba versus placebo, Outcome 7 Initial claudication distance (expressed as kilocalories) after 12 to 16 weeks.

Comparison 1 Ginkgo biloba versus placebo, Outcome 8 Initial claudication distance (expresses as kilocalories) after 6 to 8 weeks.
Figuras y tablas -
Analysis 1.8

Comparison 1 Ginkgo biloba versus placebo, Outcome 8 Initial claudication distance (expresses as kilocalories) after 6 to 8 weeks.

Comparison 1 Ginkgo biloba versus placebo, Outcome 9 Ankle brachial index and ankle pressure at the end of study.
Figuras y tablas -
Analysis 1.9

Comparison 1 Ginkgo biloba versus placebo, Outcome 9 Ankle brachial index and ankle pressure at the end of study.

Comparison 1 Ginkgo biloba versus placebo, Outcome 10 Quality of life (expressed as a Visual Analoque Scale for complaints).
Figuras y tablas -
Analysis 1.10

Comparison 1 Ginkgo biloba versus placebo, Outcome 10 Quality of life (expressed as a Visual Analoque Scale for complaints).

Comparison 1. Ginkgo biloba versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Absolute claudication distance (expressed as kilocalories) at the end of the study Show forest plot

11

477

Mean Difference (IV, Random, 95% CI)

3.57 [‐0.10, 7.23]

2 Absolute claudication distance (expressed as kilocalories) after 24 weeks Show forest plot

6

321

Mean Difference (IV, Random, 95% CI)

4.72 [2.27, 7.16]

3 Absolute claudication distance (expressed as kilocalories) after 12 to 16 weeks Show forest plot

8

339

Mean Difference (IV, Random, 95% CI)

1.36 [‐2.63, 5.36]

4 Absolute claudication distance (expressed as kilocalories) after 6 to 8 weeks Show forest plot

5

236

Mean Difference (IV, Random, 95% CI)

2.19 [‐0.62, 4.99]

5 Initial claudication distance (expressed as kilocalories) at the end of the study Show forest plot

13

723

Mean Difference (IV, Random, 95% CI)

1.84 [‐0.92, 4.61]

6 Initial claudication distance (expressed as kilocalories) after 24 weeks Show forest plot

8

564

Mean Difference (IV, Random, 95% CI)

2.15 [‐2.06, 6.36]

7 Initial claudication distance (expressed as kilocalories) after 12 to 16 weeks Show forest plot

9

441

Mean Difference (IV, Random, 95% CI)

1.54 [‐0.04, 3.12]

8 Initial claudication distance (expresses as kilocalories) after 6 to 8 weeks Show forest plot

6

335

Mean Difference (IV, Random, 95% CI)

2.72 [0.75, 4.69]

9 Ankle brachial index and ankle pressure at the end of study Show forest plot

6

274

Std. Mean Difference (IV, Random, 95% CI)

‐0.22 [‐0.58, 0.15]

10 Quality of life (expressed as a Visual Analoque Scale for complaints) Show forest plot

5

208

Std. Mean Difference (IV, Random, 95% CI)

0.38 [‐0.94, 1.70]

Figuras y tablas -
Comparison 1. Ginkgo biloba versus placebo